Deals in Depth: May 2010
Alliance leaders included GSK's €73.9 million investment in new partner Dong-A Pharmaceutical and Medtronic's $70 million investment in cardiovascular device company BioControl. Abbott led biopharma M&A activity with its $3.7 billion purchase of Piramal's healthcare solutions business. In devices, Endo paid $221 million up front for HealthTronics. Roughly 30 percent of the month's $953 million in biopharma fundraising came from Salix's $291 million debt deal. No public device dollars were realized in May, though 11 companies completed venture rounds.
You may also be interested in...
The US agency has released a document explaining what COVID-19 testing supplies may be substituted.
Marketing consultant Buzzback surveyed 800 consumers in March, prior to novel coronavirus shutdowns in the two countries, to identify ingredients that offer opportunities for brands in health care, wellness and skin care.
AstraZeneca and Accent Therapeutics will jointly discover, develop and commercialize novel therapeutics targeting RNA-modifying proteins for the treatment of cancer.